Table 1 Baseline Characteristics
Variables | Unweighted | IPTW Weighted | ||||
|---|---|---|---|---|---|---|
Historical Controls N = 140 | 2nd line Ipilimumab N = 189 | P-value | Historical Controls N = 288.4 | 2nd line Ipilimumab N = 311.2 | Weighted standardized difference | |
Age at second line (years), mean (SD) | 55.2 (12.7) | 61.7 (13.6) | <.001 | 57.5 (18.5) | 59.5 (17.9) | 0.11 |
Males, n (%) | 96 (68.6) | 127 (67.2) | 0.79 | 66.63% | 67.71% | 0.02 |
Income quintile, n (%) | 0.41 | |||||
Lowest | 18 (12.9) | 20 (10.6) | 11.47% | 10.39% | 0.03 | |
Medium to Low | 21 (15.0) | 28 (14.8) | 15.73% | 16.47% | 0.02 | |
Medium | 37 (26.4) | 37 (19.6) | 26.00% | 16.99% | 0.22 | |
Medium to High | 28 (20.0) | 52 (27.5) | 19.88% | 26.89% | 0.17 | |
Highest | 36 (25.7) | 52 (27.5) | 26.93% | 29.26% | 0.05 | |
Urban, n (%) | 121 (86.4) | 167 (88.4) | 0.60 | 88.53% | 89.12% | 0.02 |
Austin morbidity score, mean (SD) | 15.9 (11.3) | 16.5 (11.9) | 0.63 | 15.99 (16.8) | 16.1 (15.4) | 0.01 |
Number of ADGs, median (IQR) | 8 (6–10) | 9 (6–11) | 0.21 | 8.3 (4.5) | 8.5 (4.4) | 0.04 |
Charlsons score, n (%) | 0.15 | |||||
0 | 123 (87.9) | 149 (78.8) | 83.5% | 82.5% | 0.03 | |
1+ | 17 (12.1) | 40 (21.2) | 16.5% | 17.5% | 0.08 | |
Prior radiation (any), n (%) | 79 (56.4) | 105 (55.6) | 0.88 | 55.40% | 56.00% | 0.01 |
Prior radiation of brain, n (%) | 30 (21.4) | 46 (24.3) | 0.54 | 22.37% | 22.98% | 0.01 |
Prior radiation other than brain, n (%) | 65 (46.4) | 74 (39.2) | 0.19 | 45.04% | 40.20% | 0.1 |
Prior resection (any), n (%) | 102 (72.9) | 139 (73.5) | 0.89 | 55.40% | 56.00% | 0.01 |
Prior brain resection, n (%) | <=5 | 13 (6.9) | 0.19 | 4.99% | 6.63% | 0.07 |
Prior other resection, n (%) | 12 (8.6) | 9 (4.8) | 0.16 | 6.69% | 6.68% | 0 |
Time from diagnosis to start of second line (months), median (IQR) | 32.5 (11.9–57.5) | 18.0 (8.4–38.5) | 0.007 | 39.9 | 42.9 | 0.04 |
Time from end of first-line treatment to start of second-line treatment (months), median (IQR) | 1.7 (1.0–3.3) | 1.0 (0.7–1.7) | < 0.001 | 1.8 | 2.6 | 0.19 |
Time from diagnosis to start of first line (months), median (IQR) | 23.7 (6.5–54.1) | 12.6 (4.1–33.7) | < 0.001 | 35.1 | 36.9 | 0.03 |
First-line treatment, n (%) | < 0.001 | |||||
Chemotherapy | 110 (78.6) | 119 (63.0) | 81.7% | 58.4% | 0.53 | |
BRAF/MEK | 13 (9.3) | 59 (32.3) | 9.7% | 36.9% | 0.68 | |
Non-ipilimumab Immunotherapy | 8 (5.7) | 8 (4.2) | 5.2% | 4.0% | 0.06 | |
Others | 9 (6.4) | <= 5 | 3.5% | 0.7% | 0.19 | |